AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Paroxysmal Nocturnal Hemoglobinuria

Recent research efforts aimed at curing Paroxysmal Nocturnal Hemoglobinuria.

Last updated

Paroxysmal Nocturnal Hemoglobinuria

Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood and bone-marrow disorder. A mutation in a blood-forming stem cell disables the PIGA gene, so affected blood cells lack protective surface proteins—including CD55 and CD59—and can be attacked by the complement system, a normal part of immune defense. This can cause destruction of red blood cells (hemolysis), anemia, fatigue, abdominal pain, kidney injury, life-threatening blood clots, and, in some people, bone-marrow failure overlapping with aplastic anemia. Current management (pubmed.ncbi.nlm.nih.gov)

PNH can affect people of many ages but is most often diagnosed in adulthood. Prognosis has improved substantially with complement-inhibiting medicines, which reduce hemolysis and clotting risk, but these treatments usually must be continued indefinitely and do not remove the mutant stem-cell clone. Current care therefore centers on complement inhibition, vaccination and infection-risk management, transfusion or anticoagulation when appropriate, and treatment of accompanying bone-marrow failure. Current management (pubmed.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been highly active, but most of it has focused on making lifelong complement control more complete, convenient, and tolerable rather than curing PNH at its stem-cell source. The central curative questions are why PIGA-mutant stem cells expand, how to safely eliminate or replace them, and whether a patient’s own corrected stem cells could eventually repopulate blood formation; at present, allogeneic hematopoietic stem-cell transplantation remains the only established curative approach, while gene correction remains preclinical. Insights into PNH emergence Haploidentical transplantation analysis (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The most important practical advance has been broader inhibition of complement, the immune pathway that destroys vulnerable PNH red cells. Traditional terminal-pathway C5 inhibitors such as eculizumab and ravulizumab prevent much intravascular hemolysis but can leave some patients anemic because red cells marked with complement fragments are cleared outside blood vessels. The C3 inhibitor pegcetacoplan addressed this upstream mechanism: in the phase 3 PEGASUS trial, it was superior to eculizumab for hemoglobin improvement in adults with persistent anemia despite eculizumab. PEGASUS trial (nejm.org)

Oral proximal-complement inhibitors have further changed the treatment landscape. Iptacopan blocks factor B, an essential component of the alternative complement pathway, and in the phase 3 APPLY-PNH and APPOINT-PNH studies improved hemoglobin and reduced transfusion needs in people previously treated with C5 inhibitors and in people new to complement treatment, respectively. These results are clinically important because an oral medicine can control both intravascular and much of the residual extravascular hemolysis, but it remains disease suppression rather than clone eradication. Iptacopan phase 3 trials (nejm.org)

Combination treatment is another strategy for persistent anemia. Danicopan, an oral factor D inhibitor, was added to eculizumab or ravulizumab in the phase 3 ALPHA trial for people with clinically significant extravascular hemolysis; at 12 weeks, hemoglobin rose by an adjusted mean of 2.94 g/dL with danicopan versus 0.50 g/dL with placebo. This demonstrates that selectively adding proximal inhibition can address an important limitation of C5 blockade, although patients still depend on continuing complement therapy. ALPHA phase 3 trial (pubmed.ncbi.nlm.nih.gov)

Longer-acting antibodies and RNA-based complement suppression are also being explored. Crovalimab is a C5 antibody designed for monthly subcutaneous administration; in COMMODORE 2, it was noninferior to eculizumab for hemolysis control and transfusion avoidance in previously untreated patients. Pozelimab plus cemdisiran combines a C5 antibody with a small interfering RNA (siRNA) that lowers liver production of C5, aiming to reduce dosing burden; however, the phase 3 ACCESS 2 study was terminated by the sponsor for a reason stated as unrelated to efficacy or safety. COMMODORE 2 ACCESS 2 record (pubmed.ncbi.nlm.nih.gov)

The clearest biologic cure strategy would be to remove the abnormal blood-forming system through donor transplantation or to repair PIGA in a patient’s own hematopoietic stem cells. Recent work has strengthened the rationale for this approach by showing that PNH clone expansion is closely linked to immune pressure against normal stem and progenitor cells in the marrow. However, no human PIGA-editing or autologous gene-therapy cure has yet become an established clinical treatment. Single-cell PNH study Insights into PNH emergence (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

Allogeneic hematopoietic stem-cell transplantation replaces the patient’s blood-forming system with donor stem cells and can eliminate the PNH clone. A 2021 multicenter Turkish analysis of 35 people with classical PNH or PNH/aplastic-anemia syndrome reported two-year overall survival of 81.2%, supporting transplantation as an option for carefully selected patients with severe marrow failure or refractory disease. A 2026 retrospective analysis of 36 patients receiving haploidentical, or partially matched family-donor, transplantation reported complete monitored PNH-clone clearance in all 32 evaluable patients, but graft-versus-host disease and transplant-related deaths remained substantial concerns. Turkish multicenter transplant study Haploidentical transplantation analysis (pubmed.ncbi.nlm.nih.gov)

Among non-curative trials, Novartis’s completed phase 3 APPLY-PNH trial tested iptacopan against continued anti-C5 treatment in people with residual anemia, while APPOINT-PNH tested iptacopan in complement-inhibitor-naive participants. APPLY-PNH registry record Alexion, AstraZeneca Rare Disease sponsored the phase 3 ALPHA study of add-on danicopan, and Roche’s phase 3 COMMODORE program evaluated crovalimab against eculizumab. These trials have produced strong evidence of improved disease control, but none was designed to eradicate PIGA-mutant stem cells. ALPHA phase 3 trial COMMODORE 2 (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers study PNH with sensitive flow cytometry, including fluorescent aerolysin (FLAER)-based testing, to measure the fraction of blood cells lacking glycosylphosphatidylinositol (GPI)-anchored proteins. Longitudinal clone measurement across granulocytes, monocytes, and lymphocytes helps distinguish persistence, expansion, and regression of PNH populations and can directly document clone elimination after transplantation. Clonal-dynamics study (pubmed.ncbi.nlm.nih.gov)

At the mechanistic level, investigators combine bone-marrow sampling, single-cell RNA sequencing, flow cytometry, and error-corrected targeted DNA sequencing. These platforms compare mutant and non-mutant stem and progenitor cells, identify immune and cell-death signaling associated with clone expansion, and may eventually reveal targets that selectively remove PNH stem cells or protect normal marrow sufficiently to restore normal blood formation. Single-cell PNH study (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Major clinical research networks include Peking University People’s Hospital and the National Clinical Research Center for Hematologic Disease in China, which reported recent haploidentical-transplant outcomes; the study acknowledged support from China’s National Key Research and Development Program through grant 2024YFC2510500. Haploidentical transplantation analysis (pubmed.ncbi.nlm.nih.gov) Academic hematology centers in Europe, Asia, and North America remain essential because PNH is rare and definitive transplant or cell-based studies require multinational collaboration.

Industry funding has driven much of the rapid therapeutic progress: Novartis supported the iptacopan phase 3 program, Alexion, AstraZeneca Rare Disease funded the ALPHA danicopan trial, and Roche developed crovalimab through the COMMODORE studies. Iptacopan phase 3 trials ALPHA phase 3 trial COMMODORE 2 (nejm.org) These investments have markedly expanded treatment options, though they are directed chiefly toward chronic complement inhibition rather than stem-cell correction.

Strengths, Limitations, and Challenges

A major strength of current research is that new inhibitors can control hemolysis more completely, improve anemia, reduce transfusions, and offer oral or less-frequent subcutaneous dosing. The limitations are equally important: complement inhibitors leave the underlying mutant clone in place, require infection-prevention measures because complement helps defend against certain bacteria, may not correct marrow failure, and can be vulnerable to breakthrough hemolysis during infections or missed oral doses. Current management Breakthrough hemolysis study (pubmed.ncbi.nlm.nih.gov)

Transplantation proves that PNH can be cured at the hematopoietic level, but its risks—including conditioning toxicity, graft failure, severe infection, graft-versus-host disease, infertility, and treatment-related mortality—make it unsuitable as routine first-line therapy for most people whose disease is controlled with drugs. A future autologous gene-editing cure would need to correct enough long-lived stem cells, preserve their ability to engraft, prevent off-target genetic changes or harmful clonal expansion, and overcome the immune environment that initially favored PNH cells. Turkish multicenter transplant study Single-cell PNH study (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

As of October 26, 2026, PNH is increasingly manageable but not close to having a broadly available drug-based cure. The most meaningful milestones to watch are safer donor-transplant protocols for people with severe marrow failure, evidence that immune or clone-selective treatments can shrink the PNH stem-cell population, and preclinical demonstration that corrected autologous hematopoietic stem cells can engraft durably without unacceptable genetic risk. Until then, the field’s near-term progress is likely to be measured in better long-term disease control and access to treatment, while transplantation remains the only established route to eliminating the disease clone. Haploidentical transplantation analysis Clonal-dynamics study (pubmed.ncbi.nlm.nih.gov)

References

Don't see your disease? Request a report